About the Company
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $JAZZ News
A Closer Look At Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...
Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual ...
Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
Originally published by Jazz Pharmaceuticals. Purple Day spotlights epilepsy and the challenges that people face when living ...
Jazz Pharmaceuticals PLC
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Jazz Pharmaceuticals gets grant for CBD preparation with at least 90% CBD and THC
Discover how Jazz Pharmaceuticals' patented CBD preparation, with over 90% CBD and a specific THC ratio, is revolutionizing disease treatment. Explore the synergistic effects of minor impurities like ...
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Jazz Pharmaceuticals' successful commercial products have shown increasing adoption and sales revenues. See why I rate JAZZ ...
Jazz Pharmaceuticals PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Jazz Pharmaceuticals PLC
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Loading the latest forecasts...